
Longeveron (LGVN) Stock Forecast & Price Target
Longeveron (LGVN) Analyst Ratings
Bulls say
Longeveron Inc's investigational product, Lomecel-B, demonstrates significant potential in treating serious conditions such as Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease, and aging-related frailty, bolstered by industry-leading survival benefits evidenced during clinical trials. The company reported a remarkable 100% five-year transplant-free survival rate in Phase 1b trial participants, suggesting a strong likelihood of FDA approval if ongoing studies achieve their endpoints. Furthermore, a revised discounted cash flow analysis, reflecting an updated weighted average cost of capital, indicates substantial upside potential for the stock, highlighting confidence in Longeveron's innovative business model and therapeutic advancements.
Bears say
Longeveron Inc has experienced a significant stock depreciation of approximately 56% year-to-date, which may be attributed to various company-specific factors that could undermine investor confidence. Key financial risks include potential safety concerns arising from the clinical development of Lomecel-B for Hypoplastic Left Heart Syndrome, as well as the possibility of inadequate efficacy results from ongoing clinical trials. Furthermore, delays in securing necessary funding for clinical advancement and uncertainties surrounding regulatory approvals may contribute to market challenges and increase the likelihood of dilution, negatively impacting the company's overall financial outlook.
This aggregate rating is based on analysts' research of Longeveron and is not a guaranteed prediction by Public.com or investment advice.
Longeveron (LGVN) Analyst Forecast & Price Prediction
Start investing in Longeveron (LGVN)
Order type
Buy in
Order amount
Est. shares
0 shares